MicroRNAs (miRNAs) are increasingly implicated in regulating the malignant progression of cancer. Here we show that miR-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. miR-9-mediated E-cadherin downregulation results in the activation of β-catenin signalling, which contributes to upregulated expression of the gene encoding vascular endothelial growth factor (VEGF); this leads, in turn, to increased tumour angiogenesis. Overexpression of miR-9 in otherwise non-metastatic breast tumour cells enables these cells to form pulmonary micrometastases in mice. Conversely, inhibiting miR-9 by using a 'miRNA sponge' in highly malignant cells inhibits metastasis formation. Expression of miR-9 is activated by MYC and MYCN, both of which directly bind to the mir-9-3 locus. Significantly, in human cancers, miR-9 levels correlate with MYCN amplification, tumour grade and metastatic status. These findings uncover a regulatory and signalling pathway involving a metastasis-promoting miRNA that is predicted to directly target expression of the key metastasis-suppressing protein E-cadherin.
Metastases are responsible for more than 90% of cancer-related mortality. These secondary growths arise through a multistep process that begins when cancer cells within primary tumours break away from neighbouring cells and invade the basement membrane 1 . This local invasion may frequently be triggered by contextual signals that carcinoma cells receive from the nearby stroma, causing them to undergo an epithelial-mesenchymal transition (EMT) 2 . Subsequently, metastasizing cells enter the circulation either directly or through lymphatics. Size constraints in the microvasculature cause many of these cells to be arrested at distant sites, where they may extravasate and enter the foreign tissue parenchyma. There they may remain dormant or, with low efficiency, proliferate from occult micrometastases to form angiogenic, clinically detectable metastases. The absence of EMT-inducing signals in the foreign microenvironment may cause such disseminated cells to revert to an epithelial phenotype by means of a mesenchymal-epithelial transition. Critical regulators of the metastatic process include both proteins and miRNAs 3, 4 .
miRNAs are small non-coding RNA molecules that suppress gene expression by interacting with the 3´ untranslated regions (UTRs) of target mRNAs 5 . In an initial real-time RT-PCR-based screen for differentially expressed miRNAs, we identified three miRNAs that are most significantly upregulated in human breast cancer cell lines -miR-155, miR-9 and miR-10b -and went on to show that miR-10b promotes metastasis 6 . Subsequently, several other miRNAs have been identified as either promoters or suppressors of metastasis [7] [8] [9] [10] [11] . In addition, the miR-200 family has emerged as a silencer of ZEB1 and ZEB2, two established EMT-inducing and metastasis-promoting transcription factors 12, 13 .
A second miRNA that stood out in our initial screen was miR-9 (ref. 6) , which is selectively expressed in neural tissues 14 and regulates their development 15 . Expression of this miRNA is also higher in brain tumours than in tumours of other histological types 16 . In clinical breast cancer, miR-9 is upregulated in primary tumours relative to normal mammary tissues 17 . miR-9 is upregulated 1,000-fold in c-myc-induced mouse mammary tumours 18 .
In a preliminary survey we used several computational algorithms, including TargetScan 19 and PicTar 20 , to search for miRNAs that target evolutionarily conserved sequences present in the CDH1 mRNA; this revealed miR-9 as the only known miRNA predicted to target CDH1 (Fig. 1a ). CDH1 encodes the epithelial cell adhesion molecule E-cadherin, a transmembrane glycoprotein that forms the core of adherens junctions between adjacent epithelial cells 21 . The cytoplasmic tail of E-cadherin associates with intracellular proteins that link it to the actin cytoskeleton 21 . Given its well-established function in maintaining adherens junctions, E-cadherin inactivation presumably promotes metastasis by enabling the dissociation of carcinoma cells from one another. In addition, its loss liberates β-catenin, which may move into the nucleus and activate pro-metastatic genes 22 . The significance of E-cadherin inactivation for metastasis has been demonstrated in models both in vitro and in vivo [22] [23] [24] [25] [26] [27] . Thus, the potential role of miR-9 as a suppressor of E-cadherin expression made this miRNA a strong candidate for promoting the acquisition of malignant phenotypes by carcinoma cells.
RESulTS

miR-9 downregulates E-cadherin expression
We stably expressed miR-9 and, as a control, miR-10b, in two epithelial cell lines ( Supplementary Information, Fig. S1 ). Ectopic expression of miR-9, but not that of miR-10b, led to an EMT-like conversion in HMLE non-transformed, immortalized human mammary epithelial cells 28 : these cells became scattered and assumed a spindle-like or star-like morphology ( Fig. 1b) and showed a 70% decrease in E-cadherin and a fivefold increase in the mesenchymal marker vimentin (Fig. 1c ). In contrast, in SUM149 human breast carcinoma cells 29 , miR-9 downregulated E-cadherin expression by about 50% but failed to induce vimentin, other mesenchymal a hs:
GCCTAAAGTGCTGCAGCCAAAGA (UTR mutant: GCCTAAAGTGCTGCAGCGTTTCT mm: Figure 1 miR-9 directly targets CDH1 and increases cell motility and invasiveness. (a) Left: predicted duplex formation between human CDH1 3´UTR (top) and hs-miR-9 (bottom). hs, homo sapien. Right: sequence of the miR-9-binding site within the CDH1 3´ UTR of human (hs), mouse (mm) and rat (rn). (b) Phase-contrast images of HMLE cells infected with the miR-9-expressing vector, miR-10b-expressing vector or empty vector. Cells were plated on 10-cm dishes at the same density (10 6 cells in 10 ml of medium). Two days after plating, images were taken and cells were counted (cell numbers are shown in parentheses). Scale bars, 20 µm. (c) Immunoblotting of E-cadherin and vimentin in HMLE and SUM149 cells infected with the miR-9-expressing vector, miR-10b-expressing vector or empty vector. β-Actin was used for loading control. (d) Luciferase activity of the wild-type (wt) or mutant (mut) CDH1 3´ UTR reporter gene in SUM149 cells infected with the miR-9-expressing vector (black bars) or empty vector (grey bars). (e, f) Transwell migration assay (black bars) and Matrigel invasion assay (grey bars) of miR-9transduced or mock-infected HMLE (e) and SUM149 (f) cells with or without ectopic expression of E-cadherin. A representative experiment is shown in triplicate along with s.e.m. in d-f. markers and a fibroblastic cell morphology ( Fig. 1c , and data not shown). These differences in response were intrinsic to the two cell lines rather than a consequence of different degrees of E-cadherin suppression, because knockdown of E-cadherin by more than 90% with short interfering RNA (siRNA) in both cell lines caused an EMT in HMLE cells 27 but not in SUM149 cells (T.T.O. and R.A.W., unpublished observations).
To determine whether miR-9 targets CDH1 directly, we performed reporter assays and found that miR-9 decreased the activity of a luciferase reporter fused to the wild-type CDH1 3´ UTR but not to a mutant 3´ UTR ( Fig. 1d) ; the latter carried altered nucleotides that were introduced in the miR-9 'seed-pairing' 19 recognition site ( Fig. 1a) . Hence, the observed downregulation of E-cadherin by miR-9 depends directly on a single cognate recognition site in the CDH1 3´ UTR.
Inactivation of E-cadherin can promote cell migration and invasion in the presence or absence of an EMT 27 . Consistent with this, ectopic expression of miR-9 led to a threefold to fivefold increase in the motility and invasiveness of both HMLE and SUM149 cells in vitro (Fig. 1e , f).
To determine whether these effects depend specifically on E-cadherin suppression, we employed an expression construct that encodes the entire E-cadherin coding sequence but lacks the 3´ UTR, yielding an mRNA resistant to miRNA-mediated suppression. Ectopic expression of E-cadherin with this construct decreased migration and invasion in miR-9-overexpressing cells but not in control cells, which have a low basal level of miR-9 ( Fig. 1e, f ). This suggests that, after miR-9 overexpression, a decrease in E-cadherin is required for cells to show increased motility and invasiveness. 
miR-9 regulates β-catenin signalling and VEGF expression
We next determined whether miR-9-mediated E-cadherin suppression would affect intracellular signalling. Binding of Wnt ligands to their receptors results in the stabilization of β-catenin, allowing it to enter the cell nucleus, interact with the T-cell-specific transcription factor/lymphoid enhancer binding factor (TCF/LEF) family of transcription factors, and promote gene transcription 30 . Independently of this, E-cadherin binds and sequesters a large pool of β-catenin at the cytoplasmic membrane, thereby preventing its nuclear translocation and its function as a component of the TCF/LEF transcription factor complex 22, 31, 32 . Our previous work demonstrated that knockdown of E-cadherin in the experimentally transformed human mammary epithelial cells caused relocalization of β-catenin from adherens junctions to the cytoplasm and nucleus 27 . Suppressing E-cadherin expression also led to decreased β-catenin phosphorylation by glycogen synthase kinase (GSK)-3β, thereby enabling the liberated β-catenin to escape proteasome-mediated degradation 27 .
In the present work, we found that miR-9-expressing SUM149 cells showed both cytoplasmic and nuclear localization of β-catenin, whereas in the control SUM149 cells this protein was predominantly associated with cell-cell junctions ( Fig. 2a ). Moreover, the β-catenin in miR-9-expressing cells showed decreased GSK-3β-dependent inhibitory phosphorylation ( Fig. 2b ) and was therefore present in a more active functional state 27, 30 .
To prove functional activation of β-catenin more definitively, we performed β-catenin reporter assays using both the Topflash construct with multiple TCF/LEF-binding sites in the promoter of a firefly luciferase reporter gene and the derived Fopflash construct with mutated TCF/ LEF-binding sites 33 . These assays demonstrated that miR-9 increased β-catenin activity more than tenfold in E-cadherin-positive cells (HMLE and SUM149) but not in E-cadherin-negative human breast cancer cells (SUM159) (Fig. 2c ). The basal β-catenin activity was far higher in SUM159 cells than in HMLE and SUM149 cells ( Fig. 2c ), which provided further indication that E-cadherin expression and β-catenin activity are inversely correlated.
Because E-cadherin inactivation promotes tumour angiogenesis in genetically engineered mouse models 22, 26 , and because the pro-angiogenic factor VEGFA has been described as a transcriptional target gene of β-catenin 22, 34 , we used the SUM149 and SUM159 breast cancer cell lines (described above and in further detail in Supplementary Information, Fig. S2 ) to determine whether miR-9 would increase the levels of VEGFA. We found that, on miR-9 overexpression, the VEGFA mRNA levels increased threefold to fourfold in SUM149 cells but not in SUM159 cells (Fig. 2d ). In addition, miR-9 suppressed E-cadherin expression and induced VEGFA expression threefold in MCF7-RAS breast carcinoma cells ( Supplementary  Information, Fig. S3 ). Thus, the ability of miR-9 to upregulate VEGFA correlates with its ability to modulate E-cadherin expression.
We tested whether the ability of miR-9 to upregulate VEGFA mRNA depended on its ability to downregulate E-cadherin expression and activate β-catenin-mediated transcription. Expression of either an E-cadherin siRNA or a constitutively active β-catenin (the ∆N90 nondegradable mutant 27 ; Fig. 2e ) in parental SUM149 cells was not sufficient to phenocopy the observed induction of VEGFA mRNA expression by miR-9; however, ectopic expression of either an E-cadherin mRNA (without a 3´ UTR) or a β-catenin siRNA ( Fig. 2e ) in miR-9-expressing SUM149 cells reversed the ability of miR-9 to induce VEGFA mRNA ( Fig. 2f ). These data indicate that E-cadherin downregulation and β-catenin activation are necessary but not sufficient for mediating miR-9-dependent VEGF upregulation. E-cadherin is therefore a critical target of miR-9, but other functionally important miR-9 targets remain to be identified.
We next implanted miR-9-expressing or mock-infected SUM149 cells into orthotopic sites: the mammary fat pads of non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice. At 12 weeks after implantation, we found a roughly fourfold increase in nature cell biology VOLUME 12 | NUMBER 3 | MARCH 2010 2 5 1 the plasma level of human-specific VEGF in mice bearing miR-9expressing SUM149 tumours in comparison with mice implanted with mock-infected SUM149 cells (Fig. 2g ), which was accompanied by a 1.5-fold increase in primary tumour weight (Fig. 2h ). We then normalized the VEGF level to the primary tumour weight for individual recipients and found that the normalized VEGF levels were still significantly higher in the miR-9 group (Fig. 2i) , indicating that miR-9-expressing tumour cells do indeed secrete more VEGF in vivo.
Finally, miR-10b, which did not decrease E-cadherin expression in SUM149 cells (Fig. 1c) , could not upregulate VEGF levels in these cells ( Supplementary Information, Fig. S4 ).
miR-9 induces tumour angiogenesis, mesenchymal traits and the formation of micrometastases
SUM149 cells forced to express miR-9 grew more slowly in vitro than the corresponding control cells ( Supplementary Information, Fig. S5 ); in contrast, in vivo the miR-9-expressing SUM149 tumours showed a roughly twofold increase in the levels of the Ki-67 cell proliferation marker compared with those having basal levels of miR-9 expression ( Fig. 3a) . Hence, the observed increase in primary tumour size seemed to reflect a cell-non-autonomous effect of this miRNA, such as its ability to enhance tumour-associated angiogenesis. To address this possibility, we performed immunohistochemistry to detect expression of the MECA-32 mouse endothelial cell antigen, a specific marker of angiogenesis. Consistent with previous observations 6 , the control SUM149 tumours showed only low levels of staining. In contrast, miR-9-expressing SUM149 tumours showed a more than tenfold increase in the density of intratumoural microvessels (Fig. 3b) , consistent with the observed higher levels of secreted VEGF. Even more robust vessel formation was observed at the outer edges of these miR-9-expressing tumours than in the intratumoural regions ( Supplementary Information, Fig. S6a ). Some of the cells within the lumina of vessels at the tumour edge were nucleated and were positive for cytokeratin expression, providing evidence for miR-9-induced intravasation of carcinoma cells ( Supplementary Information, Fig. S6a, b) . Although most of the carcinoma cells within the miR-9-expressing and control tumours had a similar morphology (Fig. 3a, b) , the carcinoma cells located near vessels at the tumour edge ( Supplementary  Information, Fig. S6a ) were cytologically different from the bulk populations of carcinoma cells (Fig. 3a, b) in the miR-9-overexpressing tumours. We reasoned that these cytologically distinctive cells were either stromal cells of host origin or carcinoma cells undergoing an EMT in vivo.
To distinguish between these possibilities, we performed immunostaining with antibodies reactive with E-cadherin and human vimentin. As expected, the miR-9-expressing tumour xenografts had weaker E-cadherin staining than control tumours (data not shown). More strikingly, a significant number of carcinoma cells at the edges of the miR-9expressing tumours showed strong staining for human vimentin, whereas intratumoural regions displayed only occasional cells positive for human vimentin (Fig. 3c) . The control tumours, which expressed lower levels of miR-9, were essentially vimentin-negative ( Fig. 3c) . Moreover, mouse fibroblasts in the tumour stroma were completely negative for human vimentin (Fig. 3c) , demonstrating that the observed vimentin-positive cells did indeed derive from implanted human carcinoma cells. Because miR-9 induced vimentin expression in cultured HMLE cells but not in SUM149 cells (Fig. 1c ), we propose that this miRNA can induce an EMT in a cell-type-dependent and context-dependent manner, and that in certain cell types, such as SUM149 carcinoma cells, miR-9 sensitizes cells to EMT-inducing signals emanating from the tumour microenvironment rather than eliciting an EMT on its own. SUM149 cells show little, if any, metastatic ability 6, 35 . Indeed, we observed that mouse hosts bearing control SUM149 primary tumours were essentially free of lung micrometastases except for one mouse, which showed a single micrometastatic cluster that was immunostained by the AE1/AE3 anti-cytokeratin antibodies at 12 weeks after implantation of cancer cells (Fig. 3d) . In contrast, the lungs of mice implanted in the mammary fat pads with miR-9-overexpressing SUM149 cells contained clusters of dense hyperchromatic cells that were positive for cytokeratins, as demonstrated by both histological examination ( Fig. 3e ) and AE1/AE3 immunostaining (Fig. 3f ). On average, we found about 14 micrometastases per 5-µm section (Fig. 3d ). This provided direct evidence that miR-9 operates as a pro-metastatic miRNA.
Silencing miR-9 inhibits metastasis
To address the question of whether miR-9 expression is required for metastasis formation by cancer cells that are naturally highly malignant, we used 'miRNA sponges' 11, 36 to knock down miR-9 stably in the highly metastatic 4T1 mouse mammary tumour cells that express a high level of miR-9 (data not shown). A 'miRNA sponge' is a construct encoding a mRNA (for example, the gfp mRNA) that contains in its 3´ UTR multiple nature cell biology VOLUME 12 | NUMBER 3 | MARCH 2010 tandem binding sites for a miRNA of interest 36 . We assessed the level of functional knockdown of miR-9 by a reporter assay, in which the predicted miR-9-binding site was introduced into the 3´ UTR of a luciferase reporter gene 6 , and found that infection of 4T1 cells with the miR-9 sponge caused a more than twofold increase in luciferase activity compared with the control sponge (Fig. 4a) ; this suggested that a more than 50% inhibition of miR-9 activity had been achieved. We then implanted the infected 4T1 cells into the mammary fat pads of syngeneic immunocompetent Balb/c mice. Four weeks later, mice were moribund as a result of primary tumour burdens in both groups, and no difference in primary tumour size was observed between the 4T1 tumours expressing a control sponge and those expressing the miR-9 sponge (Fig. 4b ). Examination of lungs revealed an average of 35 visible metastases in mice implanted with 4T1 cells expressing the control sponge (Fig. 4c, d) ; in contrast, a roughly 50% decrease in lung metastases (an average of 17 visible metastases per mouse) was observed in mice bearing 4T1 tumours expressing the miR-9 sponge (Fig. 4c-e ). Thus, inhibition of miR-9 can suppress metastasis formation by otherwise highly malignant cancer cells.
MYC/MYCN activates miR-9 expression
Consistent with our previous findings 6 , HMLE cells naturally expressed a low level of miR-9, whereas the breast cancer cell lines examined expressed higher levels of this miRNA (Fig. 5a) . A correlation between RAS status and miR-9 levels was observed in various cell lines; for instance, both the MCF7-RAS human breast cancer cells, which express an introduced, activated RAS oncoprotein (H-RASV12) 37 , and the MDA-MB-231 human breast cancer cells, which contain an activating K-RAS, codon 12 mutation 38 , showed significantly higher miR-9 levels than did the HMLE and MCF7 cells, both of which lack an activated RAS oncogene 38 (Fig. 5a ). Relative to miRNA expression in normal mammary tissues, miR-9 stood out as the top upregulated miRNA in mammary tumours in the MMTV-c-myc transgenic mice 18 . We found this to be particularly interesting because RAS can potentiate MYC activity to promote tumour angiogenesis 39 and induce VEGF expression 40 .
MYC directly regulates the expression of a diverse set of miRNAs (for example the oncogenic miR-17-92 cluster) that contribute to tumorigenesis [41] [42] [43] . We ectopically expressed MYC in HMLE cells and found that a fourfold increase in MYC expression level resulted in a roughly threefold increase in the level of mature miR-9 (Fig. 5b) . miR-9 can be generated by the processing of any of three primary transcripts encoded by three distinct genes. Among the three encoding genes, the transcription of mir-9-3 is upregulated most strongly (3.9-fold; Fig. 5b ) by MYC.
Another MYC gene family member, MYCN (N-MYC), is frequently amplified in neuroblastomas. Operating as transcription factors, MYC and MYCN share a common set of target genes and are functionally interchangeable 44 . To evaluate whether MYCN can also upregulate miR-9, we measured its expression in a MYCN-inducible model system, SHEP-MYCN-ER 42 . On 4-hydroxy-tamoxifen (4-OHT)-mediated activation of the MYCN-ER fusion protein, miR-9 expression level increased fourfold, which was comparable to the increase in expression of the miR-17-92 positive control, whose expression is activated by MYCN through direct promoter binding 45 (Fig. 5c ).
To determine whether MYC and MYCN regulate the expression of miR-9 by binding directly to the corresponding genomic sequences, we performed genome-wide chromatin immunoprecipitation (ChIP)on-chip experiments with the Kelly and SJ-NB-12 neuroblastoma cells, which express high levels of endogenous MYCN and MYC, respectively, as a result of gene amplification. We observed that the endogenously expressed MYCN and MYC proteins bound directly to a conserved CpG island region encompassing canonical MYC-binding sites (5´-CACGTG-3´) in the mir-9-3 locus; this was observed in both the Kelly and SJ-NB-12 neuroblastoma cells (Fig. 5d) .
The association of chromatin-bound MYC with H3K4me3 (histone H3 trimethylated at lysine 4, a mark of activated chromatin) at MYCregulated genes has been described previously 46 . Indeed, we found that binding of MYC at the mir-9-3 locus was associated with elevated H3K4me3 binding ( Supplementary Information, Fig. S7 ). Although we also observed a peak for MYC binding at mir-9-1 and mir-9-2 loci, these two regions showed low occupancy by H3K4me3 and relatively high occupancy by H3K27me3 (a mark of repressed chromatin, data not shown). Hence, of the three miR-9-encoding genes, the transcription of mir-9-3 is the most responsive to transcriptional activation by MYC/MYCN. Recently, others have identified candidate transcriptional start sites (TSSs) and promoters of the great majority of human and mouse miRNA genes 47 . They exploited yet other findings that histone H3 is trimethylated at lysine 4 at the TSSs and promoters of most genes (more than 90%) in the genome. This study identified position 87712233 of chromosome 15 as the putative human mir-9-3 TSS 47 . In the present study we observed co-occupancy by H3K4me3 and MYC of this putative mir-9-3 TSS region (close to position 87712000; Supplementary Information,  Fig. S7 ), as well as of a region upstream of this putative mir-9-3 TSS (near position 87708500, where a canonical E-box is located; Supplementary  Information, Fig. S7 ). Hence, the regions in which we observed MYC binding seem to encompass the mir-9-3 TSS and promoter, providing further evidence of transcriptional regulation of the mir-9-3 gene by MYC.
Correlation of miR-9 with MYCN amplification, tumour grade and metastatic status in human cancers
To extend our analysis to clinical cancers, we measured the expression of miR-9 in a cohort of 45 neuroblastoma tumour samples. Twentytwo tumours had a normal MYCN copy number and were classified as stage 1 (n = 10), stage 2 (n = 6) or stage 3 (n = 6) neuroblastomas. Twenty-three tumours were classified as stage 4 neuroblastomas, and all showed MYCN gene amplification. In comparison with tumours with normal MYCN copy number, tumours that showed an amplification of the MYCN gene showed a 2.5-fold upregulation of miR-9 expression (P = 9 × 10 −4 ; Fig. 6a ). The observed increase in miR-9 expression was similar to that of the miRNAs belonging to the miR-17-92 cluster (the average increase in miR-17-92 was 2.6-fold; Supplementary Information,  Fig. S8 ), which was previously shown to be upregulated in MYC/MYCNoverexpressing tumours 42, 48 .
We also examined miR-9 levels in clinical breast cancers. Consistent with our expression analyses of cultured cell lines, miR-9 levels were significantly elevated in primary breast tumours from patients with diagnosed metastases in comparison with those from metastasis-free patients (4.33-fold increase, P = 0.007; Fig. 6b ).
DiSCuSSiON
We identify miR-9 as a pro-metastatic miRNA and a negative regulator of the key metastasis suppressor E-cadherin. On the basis of our results, we propose that the MYC and MYCN oncoproteins, acting on the mir-9-3 locus, activate miR-9 expression in tumour cells. The miR-9 miRNA can suppress the expression of E-cadherin to promote carcinoma cell motility and invasiveness and to activate β-catenin signalling; the latter, in turn, contributes to an elevated expression of VEGFA, leading to induction of tumour-associated angiogenesis. Ultimately, both increased cell motility and invasiveness, as well as enhanced angiogenesis, contribute to metastasis formation (Fig. 6c) . Because E-cadherin downregulation and β-catenin activation seem to be necessary but not sufficient for mediating miR-9-dependent VEGF upregulation, other miR-9 targets must also operate to enable VEGF induction by this miRNA (Fig. 6c) .
A recent study showed that miR-9-encoding gene promoters, as well as the promoters of genes encoding two other miRNAs (miR-34b/c and miR-148a), were methylated in a relatively large fraction of primary tumours present in patients with lymph node metastases; in contrast, only a small fraction of primary tumours from patients without lymph node metastases showed methylation at this promoter, although the status of distant metastases of these tumours was not determined 49 . However, because the miR-9 expression levels in these tumours were not determined, it remains unclear whether there was a correlation between miR-9 gene methylation status and miR-9 miRNA levels. Furthermore, when ectopically expressed in several highly malignant cells, miR-34b/c and miR-148a suppressed metastasis formation, whereas miR-9 did not 49 .
Yet other evidence indicates that miR-9 is positively associated with malignancy of human cancers. miR-9 expression is significantly upregulated in both clinical breast cancers 17 and in c-myc-induced mouse mammary tumours 18 . We have found that miR-9 is upregulated in various breast cancer cell lines in comparison with non-transformed mammary epithelial cell lines, and that metastatic breast cancer cells express even higher levels of miR-9 than non-metastatic tumour cells. miR-9 is also upregulated in metastatic breast tumours in comparison with nonmetastatic breast tumours from patients (Fig. 6b) . These results suggest that methylation of the promoters of miR-9 genes reported 49 does not indicate a wider role of this miRNA in inhibiting metastasis.
In contrast to miR-10b, which is specifically upregulated in metastatic cancer cells 6 , miR-9 expression is upregulated in both metastatic and non-metastatic tumour cells relative to non-transformed cells. These observations, together with the fact that miR-9 expression can be upregulated by MYC and MYCN oncoproteins, suggest that miR-9 expression is often induced at earlier stages of multistep tumour progression when elevated MYC and MYCN expression is already apparent 50 , but before tumours become actively invasive and metastatic.
Can miR-9, acting on its own, initiate the EMT programme? In the SUM149 carcinoma cells, the partial decrease in E-cadherin levels mediated by this miRNA does not directly induce an EMT in vitro; instead, it seems to sensitize these tumour cells to EMT-inducing signals arising from the tumour microenvironment. This leads to the acquisition by carcinoma cells of mesenchymal traits late in tumour progression, which could contribute to metastatic dissemination.
We observed a contrasting response in HMLE cells, in which there was an EMT-like conversion resulting from overexpression of miR-9. One possibility is that miR-9 might induce an EMT in a cell-type-dependent and context-dependent manner; for example, HMLE cells have undergone functional inactivation of both p53 and retinoblastoma gene product (Rb), which might prime these cells for induction of an EMT. Alternatively, the apparent ability of miR-9 to induce an EMT in HMLE cells might be explained by selection for a pre-existing rare mesenchymal subpopulation present within this particular cell line 51 . Unlike the HMLE cell line, the SUM149 cell line does not contain a detectable mesenchymal subpopulation, as determined by the absence of detectable levels of the mesenchymal marker vimentin (Fig. 1c ) and on fluorescence-activated cell sorting profiles (data not shown). For this reason, the selection mechanism, if it ever occurs, applies to HMLE cells but not to SUM149 cells, and the conclusions drawn from SUM149 experiments are unaffected.
Inactivation of the key metastasis suppressor E-cadherin can occur through distinct mechanisms, such as promoter hypermethylation and the actions of various EMT-inducing transcription factors. Our findings identify an additional mechanism for downregulating E-cadherin and indicate that elevated expression of the miR-9 miRNA may contribute to EMT and metastasis in some and possibly many human tumours.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturecellbiology/ Note: Supplementary Information is available on the Nature Cell Biology website.
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Figure S1 Expression of miR-9 and miR-10b in HMLE and SUM149 cells infected with the miR-9-expressing, miR-10b-expressing, or empty vector.
RT-PCR of miR-9 and miR-10b was performed using the mirVana qRT-PCR miRNA Detection Kit for mature miRNAs. 
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Figure S4 miR-9, but not miR-10b, increases plasma levels of VEGF in tumor-bearing mice. Plasma levels of VEGF in mice that received orthotopic injection of miR-9-expressing, miR-10b-expressing or mock (MDH)-infected SUM149 cells were measured by ELISA, at week 12 after transplantation. Data are presented as mean ± s.e.m. (n = 3 mice per group). 
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